First profiling of the national Swiss Clinical Quality Management giant cell arteritis and polymyalgia rheumatica registry

The SCQM registry provides real-world data on the management of GCA-PMR spectrum disease (GPSD) patients. Imaging has largely replaced histology for GCA diagnosis. Despite 75% of GCA patients receiving tocilizumab, one-third remained on glucocorticoids beyond 2 years. Such registries are expected to optimise care for this often fragile GPSD population.